Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
The purpose of this study is to evaluate safety and reactogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) manufactured by GPO, Thailand, and to evaluate humoral immune response of the above vaccine after intranasal application by using HAI test, micro neutralization assays.
Epistemonikos ID: ed76eb7cf553a2bb7664c7f4ca497ba281f73f4e
First added on: May 11, 2024